This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Well Characterized Biologics & Biological Assays

Savings Deadline Ends In:

  • 00
  • 00
  • 00
  • 00
November 1-3, 2022
College Park Marriott Hotel & Conference CenterHyattsville, Maryland, USA

Wendy Walton
Bioproduct Research and Development at Eli Lilly and Company


Wendy Walton earned her M.S. in Biology at Wichita State University and her Ph.D. in Molecular Biophysics from Florida State University. Her graduate studies were focused on studying glycoprotein structure and function. Wendy has 16 years of experience in the bioassay space within the biopharmaceutical industry. Wendy is currently in the Bioassay Development group in the Bio-product Research and Development organization of Eli Lilly and Company. In this role, Wendy performs a variety of functions to evaluate the potency of therapeutics in Lilly’s pipeline and is especially interested in understanding molecular attributes in biological therapeutics that impact potency and effector function.

Agenda Sessions

  • Approaches to Increase Efficiency in Bioassay Development and Testing